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This longitudinal survey aimed to analyse the fatigue experienced over 12 months by a 
gynaecological cancer population, to determine if the fatigue was more severe than that 
reported by females without cancer and to identify variables associated with cancer 
related fatigue (CRF) . Data was collected over a 12 month period before, during and 
after anti-cancer treatment. Fatigue was assessed using the Multidimensional Fatigue 
Symptom Inventory-Short Form. Participants with cancer also completed the Rotterdam 
Symptom Checklist (RSCL).  Sixty-five cancer patients (mean age = 57.4, SD 13.9) and 
60 control subjects (mean age 55.4, SD 13.6) participated. Descriptive analysis indicated 
that the pattern of CRF differed depending on cancer treatment received. Regarding 
fatigue severity, the cancer participants reported worse fatigue than the non-cancer 
individuals. The pattern of fatigue over time also appeared to vary between the two 
groups. Repeated Measurements Modeling (RMM) confirmed that females with cancer 
had significantly greater fatigue than females with no cancer history at all time points (p 
< 0.001) and that the level of fatigue changed with time (p = 0.02). Individuals with 
gynaecological cancer experienced significantly worse fatigue than non-cancer females 
during and after treatment, and fatigue persisted long after treatment was complete. A 
forward stepwise regression demonstrated that psychological distress level was the only 
independent predictor of CRF during anti-cancer treatment (p < 0.00), explaining 44% of 
the variance in fatigue. After treatment, both psychological distress level (p < 0.00) and 
physical symptom distress (p = 0.03) were independent predictors of fatigue, accounting 
for 81% of the variance. Psychological distress level is an important indicator of CRF in 
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gynaecological cancer. Interventions focused on the reduction of psychological distress 
may help alleviate CRF.
Keywords: fatigue; neoplasm; gynaecological; symptoms; adult.
Running title: Fatigue in gynaecological cancer
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Introduction
Cancer-related fatigue (CRF) is an almost universal symptom in patients receiving anti-
cancer therapy (1). CRF can have a phenomenal impact on a patient’s life (2) and can 
hinder the chance of remission or even cure, owing to the direct influence it can have on 
the individuals desire to continue with treatment (3). Research has indicated that 
individuals with gynaecological cancer experience more severe fatigue than those with 
other cancer diagnoses (4). In a UK multi-centre survey of 576 cancer patients with 
varying diagnoses, half of which were currently receiving anti-cancer treatment, over 
50% reported fatigue as their biggest problem. It was concluded that fatigue had a much 
greater effect on individuals with cancer than any other physical or mental consequence 
of the disease or its treatment (5). Furthermore, a pilot study indicated that fatigue is a 
significant problem for females with gynaecological cancer at various stages of their 
disease and treatment process (6). It was therefore deemed appropriate and necessary to 
further examine fatigue in gynaecological cancer.
A number of methodological limitations have been highlighted in the research to date (7-
9). Three main problems have been emphasized, firstly, there is a degree of uncertainty 
surrounding the best approach for CRF assessment, thus a variety of self-report measures 
exist. Many of these measures are single item, which are therefore inadequate to measure 
fatigue, a multidimensional construct. The most appropriate and valid approach would be 
to use a multidimensional measure (8). Secondly, a number of investigations are cross-
sectional in design which has restricted the conclusions that can be drawn with regard to 
fatigue as an ongoing symptom. A more methodologically sound approach is to 
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undertake a longitudinal survey, to enable fatigue to be charted accurately over time. 
Fatigue is also a common complaint among the general population which must be taken 
into consideration when reporting the prevalence of symptoms among cancer patients (9). 
The most effective approach for the management of a symptom such as fatigue is to 
identify and treat the source of the symptom (10). It has been suggested that CRF is 
linked with tumour and/or treatment related variables. In a baseline assessment before 
anti-cancer therapy lung cancer produced significantly higher fatigue prevalence than 
breast or prostate cancer (11). In a chemotherapy study of breast and ovarian cancer 
patients, those with a diagnosis of ovarian cancer experienced worse fatigue (4). It is 
plausible that fatigue severity increases with advancing stage of the disease (10), however 
CRF has also been shown to be unrelated to disease stage (12). Fatigue is frequently 
reported as a common side effect of most chemotherapy regimes; nevertheless there have 
been some conflicting findings in this area (13). It has been reported that patients 
receiving radiotherapy complain of fatigue which may be influenced by factors that are 
unique to radiotherapy such as radiation dose, target field and radiation quality (14). 
However, fatigue has also been shown to be unrelated to radiotherapy (15). 
Many authors have postulated anemia as a cause of CRF (3,10,16-18) either related to the 
disease itself or due to the anti-neoplastic therapy. Once more however a disagreement 
exists in the literature (19).
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As a result of an interaction between the tumour and the host’s defense system (18) 
cytokines are released in greater amounts in cancer patients. It has previously been 
suggested that cytokines such as TNF can alter central serotonin levels and hence the 
perception of fatigue (3). This serotonin dysregulation may help explain the development 
of CRF although the issue of cytokine release contributing to CRF remains controversial 
(10).
Psychosocial factors may have a role to play in the development of CRF. CRF has been 
associated with mood disturbance (20), anxiety, depression and difficulty sleeping (17). 
Furthermore, it has been reported that personality type and stress can also lead to a 
greater perception of fatigue severity (16).  In contrast it has been reported that an 
increase in the level of fatigue does not relate to a concurrent increase in anxiety and 
depression or sleep quality (21). 
The conflict and controversies present in the literature have left the etiology of CRF 
unclear. It is important to understand the factors associated with CRF as without this 
understanding, the prevention and management of the condition becomes very complex. 
Aims
The study aimed to analyse prospectively the onset and pattern of fatigue, if any, 
experienced over a 12 month period by a gynaecological cancer population, and 
determine if the fatigue experienced was more severe than the fatigue experienced by 
matched non-cancer volunteers. The study also aimed to explore the variables associated 
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with CRF during and after anti-cancer treatment and identify those associated with more 
severe fatigue in gynaecological cancer.
8
Methods
Ethical approval was obtained from the Central Office of Research Ethics Committees 
(COREC) (January 2005). 
Participants
Information was obtained from gynaecological cancer patients from the Belfast City 
Hospital, Southampton General Hospital and United Bristol Healthcare Trust. Data for 
comparison purposes was collected from a group of age matched females, with no history 
of cancer. Participants in the non-cancer group were recruited via a peer nomination 
process (22,23). When the cancer subject could not nominate a suitable match a control 
was assigned to them from a list of eligible volunteers created before the commencement 
of the survey. 
Inclusion/exclusion criteria
Included cancer subjects were newly diagnosed with gynaecological cancer having 
received no treatment, except surgery, for their disease to date, with no previous 
diagnosis of cancer. They had to be fully informed of their diagnosis, be 18 years or 
older, be English speaking and have provided informed consent. Individuals attending a 
clinical psychologist or psychiatrist, with cognitive impairment or incompetence, with a 
chronic disease in which fatigue was a prominent symptom or those with a serious 
underlying medical condition were excluded.
Included non-cancer females were 18 years or older and within 5 years of their matched 
cancer subject. They had to be English speaking and have provided fully informed 
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written consent. The exclusion criteria were as for the cancer participants; in addition the 
cancer participant’s primary carer was excluded. 
Procedure
Cancer participants
Data was collected at predetermined intervals over a twelve-month period. This 
commenced following surgery, prior to anti-cancer treatment. At baseline participants 
were asked to complete a demographic questionnaire. Data on fatigue was obtained using 
the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF). The cancer 
participants were invited to complete the MFSI-SF weekly during their anti-cancer 
treatment for a maximum of twelve weeks. Once a participant had completed treatment or 
reached the twelve-week cut off point, they moved on to monthly completion of the 
MFSI-SF thus reducing patient questionnaire burden. The Rotterdam Symptom Checklist 
(RSCL) was completed by the cancer participants on a monthly basis for the twelve 
months. 
Non-cancer volunteers
The non-cancer comparison group was required to complete the initial demographic 
questionnaire and the MFSI-SF. The fatigue questionnaire was completed on a monthly 
basis for the twelve-month duration. 
Any individual that did not wish to participate or withdrew was invited to score their 




Information on age, marital status, number of dependents, employment status and normal 
activity levels was obtained. Relevant medical data was acquired from participant 
medical records.
MFSI-SF
The 30 item MFSI-SF has five subscales: general (GF), physical (PF), emotional (EF) 
and mental fatigue (MF) and vigor (V). The respondent indicates the extent to which they 
have experienced each symptom during the preceding week (0 = not at all; 4 = extremely) 
(24). Ratings are summed to obtain scores for each of the subscales detailed previously. 
In addition, a total fatigue (TF) score can be generated by summing the four fatigue 
subscales and subtracting the vigor subscale (24). 
RSCL
This is a well established (25), cancer-specific tool designed to assess physical and 
psychological distress over the past week, on a 30 item, four point Likert scale (26). It 
appears to be a feasible measure of quality of life (27). This provided a more 
comprehensive picture of each participant’s cancer experience and helped to monitor 
activity levels through the generation of an activity level score. 
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Statistical analysis
Data analysis was performed using the Statistical Package for the Social Sciences (SPSS) 
Version 11 for Windows. 
Sample size
A previous study provided MFSI-SF scores for cancer participants and non-cancer 
controls (28). Based on the difference of scores on the general fatigue subscale between 
these two groups a power calculation was conducted and it was determined that for 90% 
power a sample of 114 was necessary. It was planned to recruit a sample of 125 to allow 
for attrition. 
After 12 months of recruitment at three cancer centres 65 individuals with a diagnosis of 
gynaecological cancer had consented to participate.  At this stage, having sought 
statistical advice there were logical reasons to look at the data (slow accrual and limited 
resources for extended data collection) (29). It was therefore decided to conduct an 
interim analysis to determine whether stopping recruitment at this stage could be 
justified. At the interim analysis stage, due to the issue of multiplicity, normal statistical 
approaches could not be used. However, analysis procedures are available to permit 
repeated statistical analysis to be performed on accumulating data. This involved the 
adjustment of the alpha level. This type of analysis allowed the stopping of recruitment if 
the information was sufficient to conclude (30). The value of the alpha was determined 
according to the total number of analyses planned (30). For this investigation, the one 
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interim analysis created two planned analyses. The O’Brien-Fleming method of using an 
alpha of 0.005 at the interim analyses and 0.048 at the final analysis stage was used (31). 
This is favourable as it uses a low p value at the interim analysis stage, thus the stopping 
criteria is quite conservative, and preserves almost the entire intended alpha for the final 
analysis stage (29). 
Interim analysis
A summary statistic was calculated for each cancer participant to indicate the change in 
PF from baseline to four weeks and baseline to twelve weeks post initiation of anti-cancer 
treatment. This was calculated from the repeated weekly administration of the MFSI-SF. 
A one sample t-test was conducted to determine if recruitment could be stopped. 
Final analyses
A univariate analysis (t-test) was used to compare the difference in fatigue scores as 
measured by the NRS-F in those who agreed to participate and those who did not, to 
detect the presence of selection bias. A similar analysis was carried out for those who 
dropped out and those who did not.
Repeated Measurements Modelling (RMM) was conducted to examine the change in 
fatigue with time and to determine whether or not those with gynaecological cancer had 
more severe fatigue than females with no history of cancer. RMM computes estimated 
marginal means (EMM) of the dependent variable. It is important to note that these show
the effect being studied without the error, not the actual observed means (32). Time and 
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group, which is cancer and non-cancer, were entered as factors. If time was not 
significant as a factor, it was entered as a covariate. The RMM was chosen as it can be 
used to describe the temporal changes of a dependent variable in a dataset with missing 
data and it is capable of treating time as a categorical variable or a continuous variable 
(33).
A forward stepwise regression with baseline Total Fatigue (TF) as measured by the 
MFSI-SF as the dependent variable was also conducted. Initially, a univariate analysis 
was undertaken to identify the individual predictors of the dependent variable. 
Independent variables included were tumour-related, treatment-related and demographic. 
Those that were identified as significant were entered into a forward stepwise regression 
with baseline TF as the dependent variable. Independent variables were entered and 
removed until the independent variables that remained in the model were all significant in 
the presence of each other. 
This analysis was repeated two times with month 2 TF (during treatment) and month 12 




Over the course of 12 months 92 individuals were identified as being eligible to 
participate. Twenty seven of the 92 declined involvement. There was no significant 
difference in NRS-F scores for participants (Mean = 4.13, SD 2.49) and non-participants 
(Mean = 3.44, SD 3.65; t = 0.886, p = 0.38). 
The demographic characteristics of the 65 participants are summarized in Table 1. The 
mean age of the cancer group was 57.4 years (SD 13.9), ranging from 23 – 86 years. The 
majority of participants were married (n = 35, 54%), not working (n = 57, 88%) with 28 
(49%) citing their cancer as their reason for not working, the majority of respondents had 
a low activity level (n = 46, 71%). 
Medical oncology data are summarized in Table 2. The most common malignancy was 
ovarian cancer (n = 35, 54%), with most tumours being stage 1 (n = 27, 42%). The 
sample was heterogeneous regarding antineoplastic treatment received. There was no 
significant difference in fatigue between those who had undergone surgery prior to 
baseline (Mean = 7.00, SD 15.81) and those who had not (Mean = 9.57, SD 19.97; t = -
0.394, p = 0.70).
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Non-cancer participants
Over the twelve months, sixty females with no history of cancer were recruited. 
Demographic characteristics are summarized in Table 1. The mean age of this cohort was 
55.4 (SD 13.6), ranging from 24 – 86. The majority were married (n = 39, 65%), 
currently working (n = 38, 63%), and had a subjectively low activity level (n = 34, 57%). 
There was no significant difference in age (p = 0.43) or marital status (p = 0.26) of those 
who had cancer and those who did not (p = 0.43).
Completion rates
Of the 65 individuals with gynaecological cancer that agreed to participate, 15 withdrew 
over the course of the twelve months. The most common reasons given were that they no 
longer wished to participate as they had finished treatment (n = 5), and disease 
progression (n = 7). A further 25 failed to complete the final 12 month questionnaire. Of 
this 25, eight had died, six had disease progression and two had been admitted to hospital. 
Consequently only 25 individuals completed the final questionnaire. A comparison of the 
final NRS-F for those who completed the study, and the last available NRS-F for those 
who dropped out indicated that there was no significant difference in NRS-F scores 
between those who completed (Mean = 4.57, SD 2.12) and those who did not (Mean = 
5.64, SD 2.41; t = -1.82, p = 0.07). Forty two of the sixty healthy volunteers completed 
the study. 
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Summary Statistics for Cancer Participants
Interim analysis
There was a statistically significant change in PF from baseline to four weeks (p = 0.001) 
and twelve weeks (p = 0.004). As these p values are less than 0.005, it was justified to 
stop recruitment. 
Final Analysis
At the end of the study, the summary statistics were repeated. As a result of the interim 
analysis, for the change to be significant, the p value had to be less than or equal to 0.048 
(31). There was a statistically significant increase in PF scores from baseline (mean = 
2.18, SD 2.98) to the mean of four weeks (mean = 4.62, SD 4.34; t = -5.03, p < 0.001). 
For those who received at least twelve weeks of anti-cancer treatment (n = 35) there was 
a statistically significant increase in PF scores from baseline (mean = 2.37, SD 2.95) to 




The mean scores for the cancer participants for each subscale of the MFSI-SF at each 
separate time-point are presented in Table 3 for weekly questionnaire completion and 
Table 4 for monthly questionnaire completion. A wide range of TF scores can be seen at 
each time-point. 
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The change in fatigue over time is summarised in Figures 1a – 1f. The level of GF and PF 
peaked during treatment and returned to approximately baseline level by the twelve 
month endpoint. The level of EF declined with time, and V improved with time. The 
level of MF remained relatively stable. Similar to GF and PF, TF peaked during treatment 
and gradually declined after anti-cancer treatment. The first and last TF measurements 
were similar. As a heterogeneous sample with regards to tumour site and anti-cancer 
treatment was recruited, it was possible to compare descriptively the impact of tumour 
site and treatment received on the pattern of fatigue during and after therapy. As can be 
noted from Figures 2a – 2c, during chemotherapy, a peak in TF was apparent at the time 
of infusion. However, during radiotherapy, there was a gradual increase in the level of 
CRF with time. After treatment, in both chemotherapy and radiotherapy, a drop in the 
level of TF was noted. The pattern of fatigue over time for ovarian and endometrial 
tumours is reflective of the patterns noted during chemotherapy and radiotherapy 
respectively. As with chemotherapy, those with a diagnosis of ovarian cancer peak TF 
was higher than the peak in TF of those with endometrial cancer. (Figure 3) 
Non-cancer participants
The mean scores for the non-cancer participants for each subscale of the MFSI-SF at each 
separate time-point are presented in Table 5. The scores for the non-cancer participants 
were much lower than those reported by the individuals with gynaecological cancer, 
indicating the females with gynaecological cancer suffered a higher level of fatigue. Over 
the course of the twelve months, the mean subscale scores for the non-cancer respondents 
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remained relatively stable. The mean TF score fluctuated around zero. A negative score 
was frequently reported, indicating that those with no history of cancer were not suffering 
from fatigue.
Repeated Measurements Modelling (RMM)
The RMM addressed three questions: did the cancer patients have more severe fatigue 
than the non-cancer volunteers; how did the profile of fatigue change with time and was 
there a group by timepoint interaction?
There was a significant difference in GF, PF, EF, MF, V and TF scores between those 
who had cancer and those who did not, those with cancer had significantly higher fatigue 
(p < 0.00). The profile or change in fatigue with time differed for different subscales; for 
GF (p = 0.038) and PF (p < 0.00) time was significant as a factor, which indicated that 
there were peaks and/or troughs in fatigue with time. Time was significant as a covariate 
for EF and TF (p = 0.03; p = 0.02 respectively) which was indicative of a linear 
downward trend, i.e. an improvement in fatigue levels with time. The level of both MF 
and V remained constant at all timepoints as time was not significant as a factor or a 
covariate. For PF a group by time-point interaction was noted. The presence of a group 
by time-point interaction indicated that at any given time-point, the two groups (that is 
cancer and non-cancer) were behaving differently. 
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Associated Variables
Before anti-cancer treatment (Baseline TF)
The independent variables included in the univariate analysis were: diagnosis, tumour 
stage, receiving surgery, marital status, age, and indications of baseline psychological 
distress level, baseline physical symptom distress level, baseline overall valuation of life 
and baseline activity level as measured by the RSCL. Significant variables were 
subsequently included in a forward stepwise regression with baseline TF as the dependent 
variable. These were baseline psychological distress level (t = 7.83, p < 0.00), baseline 
overall valuation of life (t = 6.62, p < 0.00), baseline physical symptom distress level (t = 
8.15, p < 0.00), and baseline activity level (t = 2.21, p = 0.03). 
The first two variables entered concurrently were baseline psychological distress level 
and baseline physical symptom distress level. Both independent variables remained 
significant in the model when entered together (baseline psychological distress level (t = 
4.50, p < 0.00), baseline physical symptom distress level (t = 4.87, p < 0.00)). As a result 
of this, baseline overall valuation of life was added to the model. All three remained 
significant in the presence of each other (baseline psychological distress level (t = 4.68, p 
< 0.00), baseline physical symptom distress level (t = 2.81, p = 0.01), baseline overall 
valuation of life (t = 3.32, p < 0.00)). Baseline activity level was subsequently entered 
into the model with the other independent variables. However in the presence of baseline 
psychological distress level, baseline physical symptom distress level and baseline 
overall valuation of life, baseline activity level was no longer significant (t = -1.09, p = 
0.28). Therefore it was concluded that baseline psychological distress level, baseline 
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physical symptom distress level and baseline overall valuation of life were the three 
independent predictors of baseline TF, explaining 68% (adjusted r square) of the 
variance.
During anti-cancer treatment (Month 2 TF)
The independent variables considered in the univariate analysis were: Baseline TF, 
treatment combination, diagnosis, tumour stage, receiving surgery, whether or not the 
participant had chemotherapy, chemotherapy regime, whether or not the participant had 
radiotherapy, radiotherapy dose, the demographic characteristics of marital status and 
age, and indications of month 2 psychological distress level, month 2 physical symptom 
distress level, month 2 overall valuation of life and month 2 activity level as measured by 
the RSCL. The variables that were significant and thus included in the forward stepwise 
regression were baseline fatigue (t = 3.78, p < 0.00), month 2 psychological distress level 
(t = 6.19, p < 0.00), month 2 overall valuation of life (t = 3.26, p < 0.00), month 2 
physical symptom distress level (t = 3.30, p < 0.00), and month 2 activity level (t = 2.08, 
p = 0.04). 
These variables were entered into a forward stepwise regression. The first two variables 
entered (with month 2 TF as the dependent variable) were baseline TF and month 2 
psychological distress level. With the two variables entered into the model concurrently, 
month 2 psychological distress level remained significant (t = 4.87, p < 0.00), but 
baseline TF was no longer significant (t = 1.58, p = 0.12). Therefore in the presence of 
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month 2 psychological distress level, baseline TF was no longer an independent predictor 
of month 2 TF. 
As baseline TF was no longer significant, it was removed from the model, and month 2 
overall valuation of life was entered in its place. Again month 2 psychological distress 
level remained significant (t = 4.84, p < 0.00), but in the presence of month 2 
psychological distress level, month 2 overall valuation of life was no longer significant (t 
= 1.08, p = 0.29). 
Month 2 overall valuation of life was removed from the model. Month 2 physical 
symptom distress level was included in the model with month 2 psychological distress 
level. In the presence of month 2 psychological distress level, month 2 physical symptom 
distress level was no longer significant (t = 0.88, p = 0.39).
Finally, month 2 activity level was entered into the model with month 2 psychological 
distress level, and the non significant month 2 physical symptom distress level was 
removed. Again month 2 psychological distress level remained significant (t = 5.44, p < 
0.00), but month 2 activity level became non significant (t = 0.30, p = 0.76).
Therefore month 2 psychological distress level as measured by the RSCL was the only 
independent predictor of month 2 TF, explaining 44% (adjusted r square) of the variance.
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After anti-cancer treatment (Month 12 TF)
The independent variables considered in the univariate analysis were: Baseline TF, 
treatment combination, diagnosis, tumour stage, whether or not the participant had 
surgery, chemotherapy regime, radiotherapy dose, the demographic characteristics of 
marital status and age, and indications of month 12 psychological distress level, month 12 
physical symptom distress level, month 12 overall valuation of life and month 12 activity 
level as measured by the RSCL. The variables entered into the forward stepwise 
regression were baseline TF (t = 3.24, p < 0.00), month 12 psychological distress level (t 
= 8.33, p < 0.00), month 12 overall valuation of life (t = 4.20, p < 0.00) and month 12 
physical symptom distress level (t = 6.17, p < 0.00). 
Initially, baseline TF and month 12 psychological distress level were entered. Month 12 
psychological distress level remained significant (t = 6.32, p < 0.00), but baseline TF 
became non significant (t = 0.87, p = 0.40). Baseline TF was then removed from the 
model, and month 12 overall valuation of life was entered with month 12 psychological 
distress level. In the presence of month 12 psychological distress level, month 12 overall 
valuation of life was no longer significant (t = 2.05, p = 0.06), but month 12 
psychological distress remained significant (t = 5.76, p < 0.00). Month 12 overall 
valuation of life was therefore removed from the model, and month 12 physical symptom 
distress level was entered in its place. Both month 12 psychological distress level (t = 
4.28, p < 0.00) and month 12 physical symptom distress level (t = 2.29, p = 0.034) 
remained significant in the presence of each other. Thus month 12 psychological distress 
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level and month 12 physical symptom distress level were the independent predictors of 
month 12 TF, explaining 81% (adjusted r square) of the variance.
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Discussion
A longitudinal survey accumulating fatigue data from a group of newly diagnosed 
gynaecological cancer patients before, during and after anti-cancer treatment was 
conducted. The methodology permitted the investigation of the pattern of fatigue both 
during and after treatment and facilitated this level of fatigue to be compared to that 
reported by females with no history of cancer. Without this comparison it would be 
unknown what proportion of the fatigue experienced by the individuals with cancer was a 
result of having cancer and receiving cancer treatment. 
The gynaecological cancer participants included in the study had more severe fatigue 
than the non-cancer females. This greater level of CRF was also apparent after treatment 
was complete. These findings are reflected in the CRF literature. It has frequently been 
reported that the fatigue experienced during anti-cancer treatment is more severe than 
non-cancer fatigue (34-37). After anti-cancer treatment, similar findings have been noted 
(35,38-43). 
Raised levels of fatigue compared to the cancer-free participants were also noted before 
the commencement of anti-cancer treatment. This could be attributed to undergoing 
surgery, that is, the effects of a general anesthetic and the trauma of surgery (35). 
However, in this sample, there was no significant difference in the level of fatigue 
reported by those who had undergone surgery and those who had not, therefore other 
factor(s) must have been responsible for the increased level of fatigue. It has been 
proposed that the increase in baseline fatigue could be due to the effects of the tumour
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itself and the psychological impact of receiving a cancer diagnosis (35).  To investigate 
this issue further, it would be useful to assess fatigue levels before surgery. However, as 
demonstrated in an earlier pilot study, it is difficult to obtain fatigue scores at this stage, 
as the individual may not be emotionally fit to participate and may be unaware of their 
diagnosis (6). 
In some subscales of the MFSI-SF the level of fatigue changed with time, indicating a 
complex pattern of CRF. This was particularly apparent in the GF and PF subscales 
where time-point was significant as a factor, indicating that fatigue fluctuated over time. 
Banthia and colleagues (2006) recommended that it was important to identify which 
dimensions of CRF were problematic and more sensitive to change over time in order to 
effectively guide treatment interventions (44). In this survey, the level of GF and PF 
reported by the cancer participants changed over the course of the 12 months, and was 
highest during anti-cancer treatment. In comparison, the MF subscale remained at a 
constant level over the course of the 12 months. The different profiles of the MFSI-SF 
subscales over time underscores the importance of measuring the different dimensions of 
fatigue, as it would appear that each dimension behaves differently over time. A number 
of studies have reported that CRF increases significantly during treatment (12,34,45-51), 
but this is not verified by all investigations (19,52,53). This inconsistency could be the 
result of methodological flaws, such as fatigue not being assessed frequently enough to 
detect fluctuations. 
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Interpretation of MFSI-SF scores
Although the change in MFSI-SF scores over time was statistically significant, the 
increase in fatigue may not have been substantial enough to have a negative impact on 
quality of life.  ‘Clinical significance’ is a term used to signify whether or not the change 
in the variable of interest is meaningful to the individual (54). Including the non-cancer 
group of females provided an indication that the fatigue was worse than the ‘norm’, but a 
more suitable method for determining clinical significance is the use of Minimal 
Clinically Important Differences (MCIDs) (54). Unfortunately there are currently no 
MCIDs available for the MFSI-SF. The National Comprehensive Cancer Network 
(NCCN) recommendations for the management of CRF suggest that anyone scoring 4 or 
more on an NRS should have their fatigue investigated further (1). In this survey, the 
overall mean NRS score for the all of the cancer participants was 4.6. This would suggest 
that the majority of gynaecological cancer patients in this study had fatigue that was 
severe enough to warrant further investigation. 
Predictors of fatigue
Fatigue before anti-cancer treatment
The regression analysis suggested that surgery was not associated with having fatigue; 
furthermore tumour related variables such as tumour site and stage were not related to 
fatigue. This suggests that the tumour site or stage for gynaecological cancer patients had 
no influence on the level of baseline fatigue reported. Increased psychological distress 
level was associated with raised fatigue at baseline, which is likely to be a result of 
receiving a diagnosis of cancer and feeling anxious about starting anti-cancer treatment. 
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Reduced quality of life and a raised physical symptom distress level were also related to 
fatigue, indicating that suffering other symptoms lead to an increase in fatigue. 
Fatigue during anti-cancer treatment
During treatment, psychological distress level was the sole independent predictor of CRF. 
A strong relationship has been noted in the literature between CRF during treatment and 
anxiety and depression (5,9,22,34,49,50,53-67). In this longitudinal survey demographic 
variables and factors associated with the tumour and anti-cancer treatment were unrelated 
to the fatigue. A large body of evidence exists to support the finding that CRF during 
anti-cancer treatment is not associated with tumour stage (12,22,23,46,51,56,60,68-70)  
or  any demographic (12,22,23,34,49,55,56,60,62,64,66-71) or treatment-related 
variables (12,22,23,46,51,53,55,60,64,68-72). In contrast, two studies have reported that 
females experience more fatigue then males (62,73), three have demonstrated an 
association between increasing age and lower fatigue (12,34,53), one between marital 
status and fatigue, with divorced women experiencing the most fatigue (74), two between 
working and raised fatigue (12,75), and one between living alone and fatigue (12). In 
contrast to the current findings the following treatment related variables have been linked 
to higher fatigue levels: receiving chemotherapy (34) and drug regime (34,74,75).
Fatigue after anti-cancer treatment
After treatment, psychological distress level was again an independent predictor of 
fatigue as was physical symptom distress level. Tumour and treatment related variables 
were not associated with the persistence of fatigue after anti-cancer therapy. Previous 
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research has also indicated strong relationships between anxiety and depression and CRF 
in cancer survivors (34,38-40,42,76-90). In agreement with the current findings the 
majority of previous research has found no relationship between diagnosis and fatigue
(35,40,42,43,76-88,91-93). Studies investigating CRF in survivors of cancer have also 
reported no association between treatment related variables and fatigue (35,38,39,41-
43,76-82,84-88,90,92-95) which concurs with the current findings. These findings, in 
conjunction with the outcome of this longitudinal survey, leads to the conclusion that in 
cancer survivors, psychological factors are related to CRF whereas tumour and treatment 
factors are not. The literature remains ambiguous with regard to an association between 
demographic variables and fatigue. In agreement with the current findings a number of 
studies have concluded that no association exists (34,42,76,78-80,83,85,87,90-96). In 
contrast, two studies reported that females experienced more fatigue than males (80,92), 
two reported that married individuals had higher fatigue than those who were not married 
(96,97). A relationship has also been reported between age and fatigue in cancer 
survivors (34,39,41,83,93,96-98). This finding is complicated by an inconsistency that 
exists between the direction of the association. For example, with testicular cancer 
patients (34,38) and participants with a hematological malignancy (87,96), the older the
subject the more fatigue reported, whereas with breast cancer patients the younger 
participants reported more fatigue (90,98). In the current survey, no association with age 
was noted. The apparent conflict of opinion that exists in this area may be due to the
difficulties in the accurate assessment of CRF.
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Psychological distress level was an independent predictor of fatigue before, during and 
after anti-cancer treatment. As has been demonstrated throughout this survey, fatigue is a 
symptom of cancer, but it is also reported to be a symptom of depressive disorders (99). 
The symptoms associated with fatigue are similar to the symptoms reported by 
individuals with depression (100). As a result of this some items included in an 
assessment scale for CRF, would be incorporated into an assessment scale for 
psychological impairment. It would be acceptable to assume some level of correlation 
between the two phenomena, and thus they would appear related in a regression analysis. 
A relationship between depression and fatigue was frequently reported in the literature. 
However, there is evidence that CRF may increase over time with no concurrent increase 
in anxiety and depression (19,21,56,101). Furthermore Jacobsen and colleagues (2003) 
reported a correlation between fatigue and depression that remained even when items 
included in both assessment scales were removed. This indicated that a relationship might 
exist that was not due to the overlap in the two assessment scales (99). The causal 
relationship between the two phenomena remains to be determined. 
In an attempt to combat the overlap in measurement, a clinical syndrome approach has 
been suggested as a more appropriate method of assessing CRF (99,100). Cella and 
colleagues (1998) developed a set of four diagnostic criteria for the International 
Classification of Diseases – 10 (ICD-10) (102). Firstly, they proposed eleven symptoms 
that could be associated with CRF. To meet the first diagnostic criteria, six of the eleven 
symptoms must be present almost every day for two weeks over the period of one month. 
One of the symptoms must be ‘significant fatigue, diminished energy, or an increased 
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need to rest, disproportionate to any recent change in activity levels’ (102). The second 
and third criteria suggest that the fatigue must interfere with usual functioning and be 
linked to cancer or cancer treatment (102). The fourth criteria states that the fatigue 
symptoms must not be a result of a psychiatric disorder and thus aims to distinguish CRF 
from psychological disorders (99). 
Limitations
Only 25 of the original 65 cancer participants completed the final assessment. However, 
the comparison of the fatigue levels, as measured by the NRS-F, of those who completed 
the study and those who dropped out demonstrated that there was no difference in the 
level of fatigue between the two at the time of withdrawal. It cannot however be 
presumed that the level of fatigue reported by those who withdrew stayed at a similar 
level as those who completed the study. Every attempt was made to minimise the attrition 
rate, however due to the nature of the disease and the severity of treatment, drop-outs, as 
in many studies, were inevitable (103). 
Not all cancer participants had a matched control, largely due to the fact that they were 
elderly participants, and it was difficult to source a match that met the inclusion/exclusion 
criteria. The omission of five non-cancer participants may have influenced the outcome 
of the survey. However, the fact that over 90% of cancer participants were matched 
would indicate that the results are more than likely the true outcome.
31
The data on CRF was only recorded up to 12 months from baseline. At the 12 month cut 
off point, the fatigue reported by the cancer participants had decreased from the level 
reported during anti-cancer treatment, but it was still significantly higher than the fatigue 
reported by the non-cancer comparison group. It is therefore unknown how long CRF 
persists for in survivors of gynaecological cancer. Future research should focus on 
investigating this fatigue persistence.
Implications for practice
Clinicians should be aware that females with a diagnosis of gynaecological cancer might
experience a raised level of fatigue before they commence treatment regardless of 
whether or not they have undergone surgery. This fatigue is likely to last throughout
treatment, and may remain after treatment. To fulfill the National Institute of Health and 
Clinical Excellence (NICE) recommendations that all patients should be offered optimal 
symptom control should they require it (104), gynaecological cancer individuals should 
be screened for high fatigue levels before commencement of anti-cancer treatment. This 
screening should continue for the duration of their treatment, and they should be 
reassessed at regular intervals once treatment is complete. Frequent assessment will help 
to ensure that appropriate interventions are made available to the patient as soon as they 
require them.
It is important to encourage the assessment of CRF clinically to ensure that fatigue is 
managed appropriately. The outcomes of this longitudinal survey demonstrate that the 
various dimensions of CRF behave differently; GF and PF peaked during treatment 
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whereas MF remained at a constant level over the twelve months. This confirms that the 
ideal approach for the measurement of CRF is with a multidimensional assessment tool. 
Clinically however it is acknowledged that it may not be possible for each individual to 
complete a multidimensional fatigue questionnaire. Where this is not achievable, it is 
suggested that individuals are screened with a single item scale such as a NRS-F, to 
identify those that require more comprehensive CRF assessment. The in depth assessment 
should measure CRF multidimensionally in an attempt to identify the source of the CRF 
so the fatigue can be managed appropriately. This recommendation has been discussed 
further by the NCCN (1). 
The apparent association between CRF in individuals with gynaecological cancer and 
psychological distress would indicate that management strategies aimed at reducing this 
distress may alleviate fatigue. Anti-depressants have been used for fatigue that is related 
to depression, but there is currently minimal research evidence to support their use 
(105,106). Psychosocial interventions such as support groups, psychotherapy, relaxation 
therapy, cognitive behavioral therapy and distraction techniques such as reading and 
listening to music have also been investigated (10,106-109).  The management of CRF 
through exercise has received the most attention in the literature (10,105,106). In this 
longitudinal survey activity level as measured by the RSCL was a univariate predictor of 
CRF. However, in the presence of psychological distress level, activity level was not an 
independent predictor of CRF. Despite this exercise has been suggested as an effective 
intervention to reduce CRF both during and after treatment (110)
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Conclusions
Fatigue is a problem for gynaecological cancer patients both during and after anti-cancer 
treatment. From this longitudinal survey it would appear that tumour and treatment 
related variables are not associated with CRF in gynaecological cancer. This suggests that 
all females with a diagnosis of gynaecological cancer, regardless of their tumour site, 
tumour stage or treatment regime should be informed that they may experience CRF 
during their treatment and that it may persist for many months once their treatment is
complete (111). This would enable the individual to provide fully informed consent to 
treatments such as chemotherapy. Research has also suggested that if an individual is told 
what to expect, they are not as likely to experience the stress of unexpected problems 
(10). Furthermore, individuals with gynaecological cancer should be reassured that the 
experience of severe fatigue is not indicative of disease progression (1). They should be 
offered education regarding effective fatigue management, for example energy 
conservation techniques such as delegation, pacing and prioritising, as recommended by 
the NCCN (1).  The strong association presented between CRF and psychological distress 
in gynaecological cancer indicates that interventions focused on the amelioration of 
psychological distress may reduce the perception of CRF in this patient population. 
Future research should focus on the investigation of the optimum management strategy 
for CRF in gynaecological cancer.
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Table 1
Cancer and non-cancer participant demographics
Cancer Non-cancer
N N
Total number of participants 65 60
Age
Mean (SD) 57.38 (13.85) 55.41 (13.60)
Marital Status
Married 35 39







Not working 57 20
Unknown 2 2
Reason for not working
Due to illness 28 -






Unknown 4 * 3**




Stayed the same 8 -
Unknown 1* -
* Totals 63 as two participants did not consider themselves to be an active person
** Does not total 60 as six participants did not consider themselves to be an active person
45
Table 2 
Gynaecological cancer oncology data (n = 65)
N






Ovarian and Uterine 1






























Gynaecological cancer oncology data (cont.)
N
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Mean TF score before, during and after anti-cancer treatment for ovarian (n = 35) 







Baseline 1 2 3 4 5 After
During Treatment
Time
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